| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5741803 | SB PHARMCO | Substituted thiazolidinedionle derivatives |
Apr, 2015
(9 years ago) | |
| US7358366 | SB PHARMCO | Thiazolidinedione derivative and its use as antidiabetic |
Apr, 2020
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5741803 (Pediatric) | SB PHARMCO | Substituted thiazolidinedionle derivatives |
Oct, 2015
(8 years ago) | |
| US5965584 | SB PHARMCO | Pharmaceutical composition |
Jun, 2016
(7 years ago) | |
| US6166042 | SB PHARMCO | Pharmaceutical composition |
Jun, 2016
(7 years ago) | |
| US6288095 | SB PHARMCO | Compounds |
Feb, 2017
(7 years ago) | |
|
US6288095 (Pediatric) | SB PHARMCO | Compounds |
Aug, 2017
(6 years ago) | |
|
US7358366 (Pediatric) | SB PHARMCO | Thiazolidinedione derivative and its use as antidiabetic |
Oct, 2020
(3 years ago) | |
| US8236345 | SB PHARMCO | Composition and use |
Oct, 2022
(1 year, 6 months ago) | |
Avandamet is owned by Sb Pharmco.
Avandamet contains Metformin Hydrochloride; Rosiglitazone Maleate.
Avandamet has a total of 9 drug patents out of which 9 drug patents have expired.
Expired drug patents of Avandamet are:
- US5741803*PED
- US5965584
- US6166042
- US6288095
- US6288095*PED
- US7358366*PED
- US8236345
- US5741803
- US7358366
Avandamet was authorised for market use on 25 August, 2003.
Avandamet is available in tablet;oral dosage forms.
Avandamet can be used as first line therapy for type 2 diabetes mellitus, treatment of type 2 diabetes mellitus.
The generics of Avandamet are possible to be released after 07 October, 2022.
Drugs and Companies using METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE ingredient
Market Authorisation Date: 25 August, 2003
Treatment: Treatment of type 2 diabetes mellitus; First line therapy for type 2 diabetes mellitus
Dosage: TABLET;ORAL
AVANDAMET family patents
